Codiak ($800mil market capitalisation), page-2

$EX1 is ludicrously undervalued if Codiak is anywhere near true value.

That's without the mountain of news that looks to be coming from the EX1 camp in 2021.

My only interest now is how long it takes for the market to twig and how high it goes.

There are only two listed pure exosome plays in the world.

We didn't really know how the market would value the research ,technology and future developments because in market terms it is a new medicine , even though off market an extensive amount of research had been done.

Now we know.